99%+ Purity Guarantee

Undergoes independent third-party verification before release. Tested to confirm ≥99% purity.

Buy Semaglutide (20 mg) Online

Name: Semaglutide (20 mg)
Brand: NOVERA COMPOUNDS
Availability: InStock

Coming Soon

Semaglutide is a synthetic GLP-1 receptor agonist for metabolic and endocrine research. It enables investigation of glucose regulation, appetite signaling, and gastrointestinal motility through GLP-1 receptor activation, supporting studies of incretin signaling pathways, energy balance regulation, and integrated central-peripheral metabolic communication.

General info

Brand	NOVERA COMPOUNDS
Strength	20mg
CAS	910463-68-2
Chemical Formula	C₁₈₇H₂₉₁N₄₅O₅₉
Molecular weight	4113.6 g/mol
Peptide Sequence	H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-OH
Synonyms	NN9535
Storage	Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.

Disclaimer: Sold as a research-grade lyophilized peptide in dry powder form. Requires reconstitution under controlled laboratory conditions. Reconstitution agents are not included.

For Research Use Only (RUO): Not for human or animal use, consumption, injection, or application. Not for diagnostic, therapeutic, or clinical purposes.

Buy More Peptides for Research Buy More Weight Loss & Metabolic Peptides Products

Free Shipping Over $1000

With fast order dispatch

Guaranteed Product Authenticity

All products contain original LOT numbers

Secure SSL
Encryption

Your data is safe with us

No Order
Minimum

Get the exact quantity you need.

Why Novera Compounds?

Precision-Synthesized Peptides

Advanced synthesis techniques ensure high structural fidelity and ≥99% purity.

Third-Party Verified Quality:

Independent laboratories confirm identity, purity, and batch consistency.

Research-Grade Reliability:

Designed for reproducible laboratory and analytical applications.

Strict Regulatory Compliance:

Products meet Research Use Only (RUO) standards and relevant laboratory regulations.

Documented Transparency:

Certificates of Analysis and quality verification reports provided for every lot.

555a76c773c8ed79615174887299fb4c5c66d2ad

Semaglutide (20 mg) About This Product

The Semaglutide peptide is a synthetic, long-acting analog of human glucagon-like peptide-1 (GLP-1) supplied as a lyophilized powder for laboratory and preclinical research. It is a 31-amino-acid linear peptide engineered with targeted substitutions and a C18 fatty diacid side chain conjugated to the ε-amino group of Lys26, a modification studied for its role in enhancing metabolic stability and prolonging systemic persistence in research models. The lipid moiety is attached via a γ-glutamic acid spacer and two 8-amino-3,6-dioxaoctanoic acid (Ado) linkers, enabling reversible albumin binding in experimental systems.

Semaglutide has an empirical formula of C₁₈₇H₂₉₁N₄₅O₅₉ and an average molecular weight of approximately 4,113.6 g/mol. Research-grade material is typically manufactured to ≥98% purity (HPLC), with identity confirmed by LC-MS and peptide mapping.

The peptide incorporates two key structural modifications: (i) substitution of alanine with 2-aminoisobutyric acid (Aib) at position 8, which confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation and extends peptide stability in vivo; and (ii) substitution of lysine with arginine at position 34, a modification associated with semi-recombinant manufacturing strategies used in advanced peptide production.

Across nonclinical investigations and clinical development programs, semaglutide has been studied for its effects on glucose regulation, appetite signaling, body-weight dynamics, and cardiometabolic biomarkers in experimental models of metabolic disease. Laboratories that buy semaglutide peptide commonly select the 20 mg vial format to support preparation of a wide range of experimental concentrations for in vitro assays and animal studies.

Semaglutide (20 mg) Key Features and Benefits

Defined GLP-1 analog structure: Synthetic 31-amino-acid GLP-1 receptor agonist with Lys26 acylation via γ-glutamic acid and Ado linkers
High analytical quality: Typically ≥98% purity verified by HPLC, with structural confirmation by LC-MS
20 mg research vial: Supports dose-ranging, formulation, and comparative pharmacology studies
Consistent physicochemical profile: Molecular weight, sequence, and lipid side-chain architecture align with materials used in nonclinical and clinical research
Broad research relevance: Studied in glucose homeostasis, appetite regulation, gastric motility, and body-weight models
Stable lyophilized format: Freeze-dried presentation supports controlled storage and transport
Research-focused supply: Frequently selected by institutions that order semaglutide peptide for metabolism and pharmacology research

For laboratory research use only. Not approved or intended for human or veterinary administration.

Semaglutide (20 mg) Mechanism & Research Applications

Semaglutide is a selective GLP-1 receptor agonist, designed to mimic and extend the activity of endogenous GLP-1, an incretin hormone involved in metabolic signaling. In experimental systems, it has been examined for its influence on multiple physiological processes relevant to energy balance:

Glucose regulation: Studied for glucose-dependent stimulation of insulin secretion and suppression of glucagon release
Gastrointestinal function: Investigated for delayed gastric emptying and altered gastrointestinal motility
Energy intake and body weight: Evaluated in large phase 2 and 3 research programs, including the STEP (SemaglutidE Treatment Effect in People with obesity) trial series
Cardiometabolic markers: Examined for changes in blood pressure, lipid parameters, and inflammatory biomarkers
Renal and hepatic endpoints: Explored as secondary or exploratory outcomes in selected studies

Within laboratory environments, Semaglutide (20 mg) is commonly used for:

In vitro GLP-1 receptor signaling assays
Pancreatic islet and β-cell biology studies
Preclinical models of food intake and body-weight regulation
Formulation, stability, and delivery-technology research

All applications remain investigational and are conducted under controlled research conditions.

Semaglutide (20 mg) Dosing & Observed Effects in Research

The following information summarizes published research protocols and clinical development data and is provided strictly for scientific context.

Injectable Semaglutide (Once-Weekly)

Initiation at 0.25 mg weekly, with stepwise escalation to 0.5 mg, 1.0 mg, 2.0 mg, and up to 2.4 mg in obesity studies
Dose-dependent changes in glycemic markers and body weight were observed, with increased gastrointestinal events at higher exposures

Oral Semaglutide (Once-Daily)

Programs evaluated 3 mg, 7 mg, and 14 mg daily doses
Escalation strategies studied to improve gastrointestinal tolerability

Higher Oral Dose Exploration

Phase 2 dose-escalation studies examined oral semaglutide with maximum doses reaching 40 mg daily using variable escalation strategies (slow, standard, and fast). These studies characterized dose-dependent efficacy and tolerability trends.
The 20 mg dose served as a mid-to-high exposure level within these escalation protocols, supporting subsequent phase 3 PIONEER trial development focusing on fixed 3, 7, and 14 mg maintenance doses.

Nonclinical Observations

Repeat-dose animal studies reported reduced food intake and body-weight changes consistent with GLP-1 receptor agonism
Rodent studies identified dose-dependent thyroid C-cell hyperplasia and embryo-fetal toxicity at relevant exposures, informing laboratory hazard assessments. Notably, the human relevance of thyroid C-cell proliferation observed in rodents remains undetermined. To date, no thyroid C-cell malignancies or increased thyroid cancer incidence have been reported in human clinical populations receiving semaglutide across multiple randomized controlled trials.

No standardized dosing exists outside controlled research settings.

Semaglutide (20 mg) Storage, Safety & References

Store unreconstituted lyophilized powder at ≤ –20°C, protected from light and moisture
Short room-temperature exposure during handling is acceptable if humidity is minimized

After reconstitution:

Store solutions at 2–8°C, protected from light
Reconstituted semaglutide is typically stable for up to 28 days when prepared with bacteriostatic water, or up to 24 hours when prepared with sterile water
Researchers should consult lot-specific stability data and follow protocol-defined requirements for their specific applications
Avoid repeated freeze–thaw cycles to preserve peptide integrity

Semaglutide is a potent bioactive research compound. Appropriate personal protective equipment and institutional biosafety procedures should be followed during handling, use, and disposal.